PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.

32 days) and showed a trend towards extended survival compared to DT2216 (median survival: 104 vs. 94 days) ( Figure 4 b).

also in 53,322 other papers

Additionally, 753b at this dosage led to a trend of extending median survival compared to DT2216; however, the difference did not reach statistical significance.

also in 111,027 other papers